Recent News and Updates

2006, 2022

Research Opportunity for Patients and Care Partners

June 20, 2022|

Enviza, in collaboration with a major pharmaceutical company, is currently conducting an online research study to better appreciate the impact of Wilson disease on patients’ lives and to better understand how symptom and treatment changes over time impact [...]

1103, 2022

Ultragenyx’s Wilson Disease Gene Therapy Program Update

March 11, 2022|

CYPRUS2+ is a randomized, double blind, placebo controlled, seamless Phase 1/2/3 study to assess safety, tolerability, and efficacy of a one-time intravenous (IV) infusion of UX701, an investigational AAV-Mediated Gene Therapy, for the treatment of Wilson Disease. Enrollment will include adults living with Wilson Disease currently being well managed on standard of care.

1003, 2022


March 10, 2022|

#GATEWAY is a Vivet Therapeutics clinical trial for #WilsonDisease, taking place at several clinical sites across the United States and Europe. Learn more about this currently recruiting clinical trial and our #Gene Therapy, VTX-801: [...]

1008, 2021

Ultragenyx Research Opportunities for Patients

August 10, 2021|

Multiple Ways to Participate in Wilson Disease Research Studies Who We Are Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company working to develop new products for the treatment of rare and ultra-rare diseases. We are committed [...]


Your support allows the WDA to maintain this website, produce educational materials, support research, and hold meetings for people living with WD, their families, and the healthcare community.

Make a Donation
Make a Cryptocurrency Donation


As a member, you have the opportunity to communicate your concerns, share your experiences, learn about the most recent advances in Wilson disease treatment and research, and contribute to important decisions that need to be made so the WDA can be a strong patient advocacy group

Join Us!


Contact Us

More Ways to Contact Us